Association Between Cardiovascular Risk Factors and the Progression of Motor and Non-Motor Symptoms in Parkinson’s Disease: A Five-Year Cohort Study
Open Access
- 23 April 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3217
Abstract
Objective: To investigate the relationship between cardiovascular risk factors and the progression of motor and non-motor symptoms in Parkinson’s disease (PD). Methods: We used data from the Parkinson’s Progression Markers Initiative (PPMI) cohort with a follow-up duration of >5 years. Baseline assessments included genetic analysis, brain MRI, cardiovascular risk factors, and overall cardiovascular disease (CVD) risk. Motor symptoms and non-motor symptoms of PD were evaluated using the Movement Disorders Society revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and sub-scores, Hoehn–Yahr stage, and Montreal Cognitive Assessment (MoCA). Statistical analyses comprised univariate and multivariate linear regression and stratified analysis. Results: A total of 169 newly diagnosed PD patients and 78 healthy controls (HCs) were included. At baseline, no significant differences in cardiovascular risk factors or overall CVD risk were observed between PD patients and HCs. Hypertension (β = 6.748, p = 0.040) and hyperlipidemia (β = 8.316, p = 0.005) were associated with faster motor progression. ApoE genotype was correlated with motor progression (β = 7.593, p = 0.007). PD patients with a moderate-to-low CVD risk (p = 0.048) and lower MDS-UPDRS Part I total scores (7.0 [IQR, 6.25] vs. 9.0 [IQR, 7.0], p = 0.039) at last follow-up compared to high-CVD-risk (≥20%) patients. Overall CVD risk was negatively correlated with total MoCA score at last follow-up (β = −0.208, p< 0.001). Conclusions: Cardiovascular risk factors accelerate the progression of motor and non-motor symptoms in PD, suggesting that management of modifiable CVD risk factors may represent a promising target to delay the progression of PD.Keywords
Funding Information
- National Natural Science Foundation of China (82071552)
- National Natural Science Foundation of China (22376006)
- Beijing Municipal Traditional Chinese Medicine Science and Technology Development Fund Project (BJZYYB-2025-57)
- Peking University Sixth Hospital Scientific Research Seed Fund (PY24003)
- Key Attending Psychiatrist Program of Peking University Sixth Hospital (BDLYYLZL2024-08)
This publication has 39 references indexed in Scilit:
- Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk EquationsJAMA, 2024
- The Evolving Landscape of Cardiovascular Risk AssessmentJAMA, 2024
- Can Cardiovascular Risk Assessment Be Improved in the 21st Century?JAMA, 2024
- 27‐Hydroxycholesterol Drives the Spread of α‐Synuclein Pathology in Parkinson's DiseaseMovement Disorders, 2023
- Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsMovement Disorders, 2023
- Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson DiseaseJAMA Neurology, 2022
- Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and ProgressionMovement Disorders, 2021
- Gait analysis with wearables predicts conversion to Parkinson diseaseAnnals of Neurology, 2019
- Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort studyMovement Disorders, 2018
- How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scaleMovement Disorders, 2013